To date, regular reviews of safety data for the trial have revealed no serious drug side effects from NX-1207 treatment. The Independent Data Monitoring Committee for the trial recently gave a positive recommendation based on evaluation of the efficacy and safety data then available.
Two earlier completed phase I and II trials of NX-1207 showed that the drug produced on average over 23% prostate shrinkage and significant symptomatic improvement in 1 month with minimal side effects. Overall there were no sexual side effects, and a better side effect profile compared to existing drugs.
Follow-up of patients from these trials have shown continued significant symptomatic improvement 29-34 months after initial treatment.
Benign prostatic hyperplasia (BHP) afflicts approximately half of men over age 50 and close to 90% of men by age 80. The disorder causes difficulties with urination associated with aging, such as urination at night, urge to void frequently, hesitancy, weak stream, and other problems.